Business Wire

TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone

16.5.2026 11:43:00 EEST | Business Wire | Press release

Share

TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/

Photograph of the MLX200 chip with a five-cent coin for size reference

The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems.

As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation directly within memory arrays, significantly reducing data movement and improving system-level efficiency. TetraMem’s MLX200 platform integrates multi-level RRAM arrays with mixed-signal compute engines to enable high-throughput vector-matrix operations within memory, while maintaining compatibility with advanced CMOS processes.

The multi-level RRAM technology demonstrated at the TSMC 22nm process provides key attributes required for practical deployment, including CMOS compatibility with minimal additional process complexity, low-voltage and low-current operation, strong retention and endurance characteristics, and high multi-level capability that supports improved memory and compute density. Early silicon results indicate consistent functionality across arrays, supporting the viability of this approach for both embedded non-volatile memory and compute-in-memory applications.

This milestone builds on TetraMem’s earlier work on the MX100 platform, fabricated on the TSMC 65nm CMOS process, where the company demonstrated multi-level RRAM devices with thousands of conductance levels (“Thousands of conductance levels in memristors integrated on CMOS,” Nature, March 2023), as well as high-precision analog computing capabilities (“Programming memristor arrays with arbitrarily high precision for analog computing,” Science, February 2024). These prior results established a strong scientific and engineering foundation for scaling the technology to more advanced nodes.

Since 2019, TetraMem has worked closely with the world leading semiconductor foundry to advance RRAM technology from early-stage research into manufacturable silicon. The progress achieved at 22nm reflects continued development in process integration, device uniformity, and system-level co-design.

The MLX200 and MLX201 platforms are designed to support power- and latency-sensitive edge AI applications, including voice and audio processing, wearable devices, IoT systems, and always-on sensing. Evaluated sampling is expected to begin in the second half of 2026, and multi-level RRAM memory IP is available for evaluation and potential licensing.

Dr. Glenn Ge, Co-founder and CEO of TetraMem, commented, “This milestone reflects years of close collaboration with our foundry partner TSMC and demonstrates the feasibility of bringing multi-level RRAM and analog in-memory computing from computing architecture breakthrough into advanced-node commercial silicon. We believe this approach provides a practical path to improving energy efficiency and scalability for next-generation AI systems.”

The successful realization of the MLX200 platform highlights the viability of multi-level RRAM-based analog computing on advanced semiconductor processes. TetraMem will continue to advance this technology to support emerging AI workloads with improved energy efficiency and system scalability.

About TetraMem

TetraMem is a Silicon Valley–based semiconductor company pioneering analog in-memory computing using multi-level RRAM technology. Its architecture integrates memory and compute to significantly reduce data movement and improve energy efficiency for AI workloads. With a strong foundation in device, circuit, and system co-design, TetraMem is advancing scalable solutions for edge AI and future high-performance computing, working closely with leading foundries and ecosystem partners to bring fundamental science breakthrough technologies into commercial variable volume production.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260516556464/en/

Contacts

Media Contact:
Glenn Ge
pr@tetramem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye